Personalized Treatment of Schizophrenia and Related Disorders with Selective Agonists and Antagonists of VPAC2R
Scientists at UC San Diego have developed a novel approach to the personalized treatment of schizophrenia and autism consisting of applying novel diagnostic and therapeutic technologies to the analysis of DNA and human cells from patients. Specifically, this invention includes generic methods for the identification of patients that carry mutations in VIPR2, and further detection of mutations in DNA that impact the function of VIPR2. These methods include DNA sequencing-based methods and microarray, PCR, and mass spectrometry-based methods for detection of DNA copy number. The invention demonstrates that the patients carrying the mutations in VIPR2 are likely to benefit from treatment with selective agonists or antagonists of VPAC2R, and/or vasoactive intestinal peptide or derivatives. As a direct implication of this finding, specific compounds that selectively modulate the activity of the VPAC2R receptor encoded by VIPR2 (e.g. selective agonists, antagonists, VIP, and/or VIP derivatives) are treatments for these and related disorders. The invention further provides a novel approach to using genetic testing to guide the selection of appropriate drugs for modulation of VPAC2R activity and consequently to treat brain disorders, such as schizophrenia and autism.This approach to personalized treatment of schizophrenia and autism consists of applying the diagnostic and therapeutic inventions described above to the analysis of DNA and human cells from patients. Overall, these findings implicate altered vasoactive intestinal peptide signaling in the pathogenesis of schizophrenia and indicate the VPAC2 receptor as a potential target for the development of new antipsychotic drugs.
Inventor: Coy, David H. | Fuselier, Joseph A. | Murphy, William A. | Sun, Lichun
Priority Number: US7326685B2
IPC Current: A61K003800 | A61K004748 | A61B000100 | A61K0031165 | A61K00314745 | A61K0031519 | A61K003804 | A61K003808 | A61K003810 | A61K003831 | A61K004742 | A61K004900 | A61K005100 | A61K005108 | A61P000100 | A61P000900 | A61P001100 | A61P001308 | A61P001500 | A61P002500 | A61P002702 | A61P003500 | C07K000706 | C07K000708 | C07K0014655
US Class: 5140111 | 514012 | 5140197 | 530311 | 530327
Assignee Applicant: The Administrators of the Tulane Educational Fund,New Orleans
Title: Diagnostic or therapeutic somatostatin or bombesin analog conjugates and uses thereof
Usefulness: Diagnostic or therapeutic somatostatin or bombesin analog conjugates and uses thereof
Summary: The peptides are useful for treating a disease selected from tumors of the lung, breast, brain, eye, prostate, or colon; tumors of neuroendocrine origin (for e.g. carcinoid syndrome), and angiogenic blood vessels (claimed). Other diseases that can also be treated using the peptides are inflammatory bowel disease, autoimmune disorders, rheumatoid arthritis, neoplastic cells or aberrantly proliferating cells, and acromegaly.
Novelty: Biologically active peptides such as somatostatin or bombesin conjugated to chemical compounds through linkers, useful for treating tumors of the lung and breast, carcinoid syndrome, and tumors of angiogenic blood vessels
生物医学
医药成分
Related Materials Tech ID/UC Case 21872/2011-199-0 Related Cases 2011-199-0
美国
